$4.69 billion. That is the amount invested in the longevity sector in the first quarter of 2024 alone, according to the Longevity.Technology Foundation. This sum exceeds the annual medical research budget of several European countries and marks transhumanism’s entry into a new phase: one of technological orthodoxy equipped with considerable financial means.
Transhumanism, the philosophy that advocates for humanity’s improvement through technology until surpassing its biological limits, is now imposing itself as the new faith of American technological elite. This ideological transformation enters into direct collision with traditional religious institutions, Pope Leo XIV having published in May 2026 his first encyclical “Magnifica Humanitas” to explicitly criticize transhumanism as “a negation of the human condition.”
The Essentials
- $4.69 billion invested in longevity in the first quarter of 2024
- Jeff Bezos, Peter Thiel, and Sergey Brin massively finance anti-aging research
- The Vatican publishes its first doctrinal position against transhumanism in the encyclical “Magnifica Humanitas”
- Longevity companies now attract as much investment as traditional biotech firms
The Money of Time: When Mortality Becomes a Market
The figures speak for themselves. Amazon Web Services generates $90 billion annually, yet Jeff Bezos dedicates a growing portion of his personal fortune to Altos Labs, an anti-aging research startup he cofounded with $3 billion. Google accumulates $307 billion in annual revenue, while Sergey Brin finances Calico, Alphabet’s longevity subsidiary. Peter Thiel, PayPal cofounder, simultaneously invests in Methuselah Foundation and research on parabiosis, the technique that involves transfusing blood from young mice to aged mice.
This concentration of capital transforms a formerly marginal sector into a structured industry. The Longevity.Technology Foundation counts 847 companies active in anti-aging research in 2024, compared to 213 in 2019. Unity Biotechnology, specializing in eliminating senescent cells, has raised $385 million. Oisín Biotechnologies develops gene therapies to reverse cellular aging with initial funding of $150 million.
The economic model is emerging. Unlike traditional biotechs that target specific pathologies, these companies attack aging itself, considered as a reversible process. BioAge Labs develops drugs to slow age-related muscle decline. Juvenescence focuses on metabolic pathways to longevity. This systemic approach attracts investors accustomed to long-term technological bets.
From Kurzweil to Altman: The Institutionalization of a Vision
Ray Kurzweil embodies this transition. Hired by Google in 2012 as director of engineering, this prophet of technological singularity has transformed his predictions into an industrial roadmap. His NBIC convergence theory (nanotechnologies, biotechnologies, computing, and cognitive sciences) now structures Alphabet’s research and development investments.
Sam Altman, CEO of OpenAI, takes this logic further. In his public writings, he predicts that artificial general intelligence will enable “solving” aging within the next fifteen years. This vision guides OpenAI’s partnerships with pharmaceutical laboratories like Moderna, which use GPT-4 to accelerate the discovery of new therapeutic molecules.
The influence extends beyond declarations of intent. Public funding follows private priorities. The U.S. National Institutes of Health increased by 67% their budget dedicated to aging research between 2020 and 2024, reaching $4.2 billion annually. DARPA finances “biological regeneration” programs directly inspired by transhumanist proposals.
This institutionalization transforms algorithmic management that is already imposing itself in enterprises into a model for human body optimization. The same performance metrics applied to employees—biometric tracking, sleep cycle optimization, cognitive enhancement—become tools for personal longevity.
The Doctrinal Counter-attack: “Magnifica Humanitas” Against Promises of Immortality
On May 15, 2026, the 135th anniversary of the encyclical “Rerum Novarum,” Pope Leo XIV signs “Magnifica Humanitas,” his first encyclical entirely devoted to artificial intelligence and transhumanism. This document of 245 paragraphs marks a historical rupture in the Vatican’s approach to new technologies.
Where the Catholic Church had adopted a nuanced approach to medical biotechnologies, it frontally rejects the transhumanist ideology that it defines as “a series of hypotheses that interpret progress as a surpassing of the human condition.” Cardinal Víctor Manuel Fernández, prefect of the Dicastery for the Doctrine of the Faith, declares during the presentation that contrary to these philosophies which claim “that humanity has reached its expiration date and must simply be replaced,” Catholic teaching believes that “every human being has infinite dignity.”
The encyclical firmly opposes transhumanism and a culture that seeks to overcome human weakness through technological manipulation. The pope rejects transhumanist ideas according to which human limitations should be technologically transcended, arguing that “vulnerability, dependence, and imperfection are essential to being human” and that “humanity flourishes not despite limitations, but often because of them.”
This position already influences European public policies. Germany and France have adopted restrictive regulations on genetic enhancement, explicitly citing Vatican positions. The Council of Europe is preparing an international convention on “the ethical limits of human enhancement” that is largely inspired by the papal encyclical.
Silicon Valley’s Reply: Between Evasion and Confrontation
Facing this doctrinal offensive, technological leaders adopt differentiated strategies. Chris Olah, cofounder of Anthropic, was exceptionally invited to the Vatican for the encyclical’s presentation alongside the pope, marking an attempt at dialogue. Olah, who says he has discussed AI with 15 different religious leaders, considers that the implications of this technology go “well beyond scientific questions” and concern “human flourishing” and “what a good world looks like.”
This Anthropic presence reveals a cooptation strategy. The encyclical recognizes that AI models like those of Anthropic have adopted “ethical constitutions,” but the pope specifies that “more moral AI is not sufficient if this morality is determined by a few.”
Other leaders remain publicly silent but discretely relocate their most controversial research. Several American longevity laboratories have opened subsidiaries in more permissive jurisdictions, notably in Singapore and the United Arab Emirates. This regulatory flight reproduces dynamics observed in other sensitive technological sectors.
Tension escalates with the Trump administration. Anthropic’s choice for the encyclical’s unveiling reflects growing tensions between Pope Leo XIV and President Donald Trump, who launched a series of criticisms after the Catholic leader condemned joint American-Israeli strikes on Iran.
The Ecosystem of Technological Faith
Silicon Valley develops its own rituals. Radical Life Extension conferences attract 2,500 participants paying $3,000 entry to hear presentations on cryogenics and consciousness uploading. Alcor, a cryonics company based in Arizona, preserves 199 bodies in liquid nitrogen, including those of several technological entrepreneurs.
Practices normalize. Intermittent fasting, popularized by research on caloric restriction and longevity, becomes routine in tech companies. Anti-aging supplements generate $4.4 billion in annual revenues, primarily from technological sector executives. Dave Asprey, creator of “Bulletproof Coffee” and figure of biohacking, directly advises several unicorn CEOs.
This culture produces its own academic institutions. Singularity University, cofounded by Kurzweil and Peter Diamandis, trains 2,000 leaders annually in “exponential technologies.” Its 10-week programs cost $15,000 and blend technological training and philosophical seminars on the transcendence of humanity.
Influence extends to venture capital. Thiel’s Founders Fund conditions certain investments on startups’ adoption of “longevity metrics” for their teams. Y Combinator, the reference accelerator, has incubated 43 anti-aging biotech startups since 2020. This convergence between investment and ideology transforms the entrepreneurial ecosystem.
The Geopolitics of Immortality
China observes and replies. The Chinese government has invested $2.8 billion in anti-aging genomic research since 2022. BGI Genomics, the Chinese sequencing giant, develops longevity gene therapies in collaboration with the Beijing Academy of Sciences. This technological race reproduces dynamics already observed in artificial intelligence where cloud giants become new landlords.
Israel bets on its biotechnological expertise. Tel Aviv University created the first university research center entirely dedicated to “reverse aging.” Its work on cellular regeneration attracts American private funding of $180 million. This strategy is part of Israel’s ambition to become the “world laboratory” of longevity technologies.
The European Union adopts a defensive position. The Horizon Europe program finances research on aging “in respect of human dignity,” a formulation that explicitly excludes transhumanist approaches. This ethical reticence could handicap European competitiveness in a rapidly expanding sector.
Russia develops its own approach. Dmitri Itskov’s 2045 Initiative aims for immortality through consciousness transfer before 2045. Although less financed than American initiatives, it benefits from tacit Kremlin support, which sees it as a means to circumvent Western sanctions on advanced biotechnologies.
The Limits of Technological Optimism
Clinical results temper enthusiasm. None of the 23 molecules tested to slow aging demonstrated significant efficacy in humans in controlled trials. Rapamycin, the most promising drug according to mouse studies, causes immunosuppressive side effects that limit its preventive use.
Costs remain prohibitive. An experimental gene therapy from Oisín Biotechnologies costs $2.3 million per patient. Cryopreservation at Alcor amounts to $200,000, plus perpetual storage fees estimated at $35,000 annually. These amounts mechanically exclude 99.8% of the world’s population.
Scientific opposition organizes itself. 147 aging biologists signed in September 2024 a column in Nature criticizing “transhumanist hype” that diverts funding from more pragmatic research. They advocate for priority investments in preventing age-related diseases rather than pursuing immortality.
American regulators strengthen their vigilance. The FDA rejected 67% of clinical trial requests for anti-aging therapies in 2024, compared to 34% in 2021. This toughening reflects concerns about efficacy and safety against often excessive therapeutic promises.
Rome Against Palo Alto: The Anthropological Clash of the Century
The papal encyclical opposes two possible trajectories: a new Tower of Babel shaped by technocratic hubris, or a New Jerusalem founded on community and solidarity. This dichotomy now structures a planetary debate on humanity’s future.
On one side, Ray Kurzweil predicts that “transhumanists like Elon Musk and Sam Altman are working on brain-computer interfaces and the merger between human and machine, while AI systems become better at controlling robots, with the long-term objective of erasing the distinction between nature and artifice.”
On the other, Pope Leo XIV denounces a vision “anti-human” where “the fullness of life is equated with having more, reducing weakness, eliminating uncertainty, and exercising total control,” transforming human beings into “projects to optimize rather than persons called to relationship and communion.”
This polarization influences American elections. Several Republican primary candidates in 2024 adopted explicitly anti-transhumanist positions, promising to strictly regulate enhancement research. On the Democratic side, positions remain nuanced, reflecting tension between the progressive electorate and the party’s technological funding.
The Vatican frontally rejects Silicon Valley’s narrative of technological neutrality: “For decades, technology companies have presented their products as neutral tools,” but “technologies inevitably reflect the intentions and values of those who create them,” transforming every technical decision into a moral choice.
The Stake: Who Will Define Tomorrow’s Human?
The confrontation transcends technical questions to touch the very essence of humanity. The encyclical introduces the concept of “digital feudalism” where “large technology companies concentrate control over data, algorithms, and digital infrastructure, effectively becoming a new class of feudal powers” whose “domains are measured not in acres of land, but in petabytes of personal data.”
This ideological battle plays out on three simultaneous fronts: investment, regulation, and collective imagination. With $4.69 billion invested in a quarter, the transhumanist movement disposes of crushing financial asymmetry. UNESCO is nonetheless preparing a universal declaration on “the ethical limits of human enhancement,” supported by a coalition of countries with strong religious traditions.
The outcome will ultimately depend on religious and democratic institutions’ capacity to propose a credible alternative vision. As the encyclical stresses, “the significance of Magnifica Humanitas lies in its capacity to shape public conversation and moral imagination. Moral frameworks matter. They influence what societies fear, what they tolerate, what they defend—and what they refuse to sacrifice.”
Money will probably continue to determine the outcome of this anthropological battle. But papal intervention transforms a technical debate into a civilizational combat whose outcome will shape humanity in the coming decades.